Introduction – Addressing Core Exocrine Pancreatic Insufficiency (EPI), Malabsorption, and Nutrient Deficiency Needs
For gastroenterologists, primary care physicians, and patients with chronic pancreatitis (inflammation of pancreas), cystic fibrosis (CF), pancreatic cancer (after Whipple surgery), or pancreatectomy, the pancreas fails to produce sufficient digestive enzymes (lipase (fat digestion), protease (protein digestion), amylase (carbohydrate digestion)). This condition, known as exocrine pancreatic insufficiency (EPI), leads to malabsorption of fats, proteins, and carbohydrates, resulting in steatorrhea (fatty, foul-smelling stools), weight loss, vitamin deficiencies (A, D, E, K – fat-soluble), and malnutrition. Compound pancreatic enzyme powder – a mixture of porcine-derived (from pig pancreas) digestive enzymes (lipase, protease, amylase) in powder form (or enteric-coated microspheres/capsules) – directly addresses these enzyme replacement, nutrient absorption, and symptom relief needs. When taken with meals, pancreatic enzyme replacement therapy (PERT) digests fats, proteins, and carbohydrates, allowing absorption and preventing malnutrition. Compound pancreatic enzyme powder is available for human use (e.g., Creon, Zenpep, Pancreaze, Pertzye) and veterinary use (for dogs with EPI). The powder formulation (or capsules containing enteric-coated microspheres) is preferred because gastric acid degrades uncoated enzymes; enteric coating protects enzymes until they reach small intestine (pH > 5.5). As the prevalence of chronic pancreatitis (estimated 5-12 per 100,000 adults), cystic fibrosis (70,000+ worldwide), and pancreatic cancer (increasing incidence) remains significant, and awareness of EPI improves (underdiagnosed), the market for pancreatic enzyme preparations across hospitals, clinics, and other settings is steadily growing. This deep-dive analysis integrates QYResearch’s latest forecasts (2026–2032), user type segmentation, and clinical insights.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Compound Pancreatic Enzyme Powder – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Compound Pancreatic Enzyme Powder market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Compound Pancreatic Enzyme Powder was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5974997/compound-pancreatic-enzyme-powder
Core Keywords (Embedded Throughout)
- Compound pancreatic enzyme powder
- Exocrine pancreatic insufficiency (EPI)
- Pancreatic enzyme replacement therapy (PERT)
- Lipase
- Chronic pancreatitis
Market Segmentation by User Type and Healthcare Setting
The compound pancreatic enzyme powder market is segmented below by both target species (type) and point-of-care location (application). Understanding this matrix is essential for pharmaceutical manufacturers targeting specific regulatory pathways (human vs veterinary) and dosage forms.
By Type (User / Indication):
- Veterinary Use (for dogs (and cats less commonly) with EPI due to chronic pancreatitis, pancreatic acinar atrophy, or congenital disorders. Administered as powder (mixed into food) or capsules. Porcine-derived enzymes. Cheaper formulations)
- Human Use (for EPI due to chronic pancreatitis, cystic fibrosis, pancreatectomy, pancreatic cancer, trauma, or after gastric bypass surgery. Available as delayed-release capsules (enteric-coated microspheres or mini-tablets) or powder packets. Requires prescription (human use))
By Application:
- Hospital (inpatient: acute pancreatitis, post-pancreatectomy, cystic fibrosis exacerbation; initiation of PERT. Administered by nursing staff)
- Clinic (outpatient gastroenterology clinics; prescription for chronic EPI; patient self-administer with meals)
- Others (home care (long-term enzyme replacement), veterinary clinics)
Industry Stratification: Human Pancreatic Enzyme Preparations
Porcine-derived pancreatic enzyme (USP) – standardized lipase units (e.g., 3,000 – 25,000 USP units of lipase per capsule). Contains lipase, protease, amylase.
Dosing: based on lipase units per meal (500-2,500 units/kg per meal). Administer with every meal and snack.
Formulation: enteric-coated microspheres or mini-tablets in capsules (or powder packets). Capsules may be opened and sprinkled on soft food (must not chew microspheres).
Brand names (US): Creon (AbbVie), Zenpep (Nestle), Pancreaze (Janssen), Pertzye (Digestive Care). Also generic.
Recent 6-Month Industry Data (September 2025 – February 2026)
- Pancreatic Enzyme Market: growing with chronic pancreatitis, CF.
- Cystic Fibrosis (November 2025): 90% of CF patients require PERT.
- Chronic Pancreatitis (December 2025): EPI often underdiagnosed.
- Innovation data (Q4 2025): generic pancrelipase (pancreatic enzyme) delayed-release capsules (lipase 3,000-25,000 USP units) available. Target: EPI.
Typical User Case – Chronic Pancreatitis (Human)
A patient with chronic pancreatitis and steatorrhea (fat malabsorption) is diagnosed with EPI.
Prescribed: pancrelipase delayed-release capsules (lipase 25,000 units) – one capsule with each meal, one with snack.
Capsules taken whole (enteric-coated microspheres).
Result: steatorrhea resolved, weight stabilized (improved fat absorption).
Typical User Case – Veterinary (Dog with EPI)
A dog with chronic diarrhea, weight loss, ravenous appetite diagnosed with EPI (low serum TLI).
Prescribed: pancreatic enzyme powder (veterinary) mixed into food (1 tsp per cup of food) before each meal.
Result: formed stools, weight gain.
Technical Difficulties and Current Solutions
Despite efficacy, pancreatic enzyme replacement therapy faces four persistent clinical considerations:
- Gastric acid degradation (enteric coating). Ensure capsules not chewed; may be opened and sprinkled onto soft food (pharmacy counsel).
- Variable dosing (different lipase units per meal). Dosing based on grams of fat per meal.
- Adherence (take with every meal, snack). Pill organizers, reminders.
- Cost (brand-name enzymes). Generic alternatives.
Exclusive Industry Observation – The Compound Pancreatic Enzyme Powder Market by User Type
Based on QYResearch’s interviews with 91 gastroenterologists and veterinarians (October 2025 – January 2026), human use dominates (prescription); veterinary use niche but essential.
Human use – 90% of market value.
Veterinary – 10% (dogs).
For suppliers, key strategy: focus on human delayed-release capsules (enteric-coated microspheres) with various lipase units (3,000-25,000); veterinary powder (cost-effective) for canine EPI.
Complete Market Segmentation (as per original data)
The Compound Pancreatic Enzyme Powder market is segmented as below:
Major Players:
Tonghua Xindongri Pharmaceutical, Harbin Pukang Herui Biopharmaceutical Co., Ltd., Jilin Province Yinhe Pharmaceutical Co., Ltd., Jilin Jinheng Pharmaceutical Co., Ltd., Shanghai Pharmaceuticals Holding Co., Ltd., Wuzhi Weikang Biochemical Pharmaceutical Co., Ltd., Sichuan Defeng Pharmaceutical Co., Ltd., Gansu Puerkang Pharmaceutical.,Ltd., Harbin Huarui Biochemical Pharmaceutical Co., Ltd., Jilin Xianfeng Technology Pharmaceutical Co., Ltd., Sunflower Pharmaceutical Group (Tangshan) Biopharmaceutical Co., Ltd.
Segment by Type:
Veterinary Use, Human Use
Segment by Application:
Hospital, Clinic, Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
